CVS Health (CVS) won’t add Gilead’s (GILD) new HIV prevention drug to its commercial plans for now, despite the medication’s proven effectiveness, a spokesperson tells Reuters, Deena Beasley reports.

California lost funding because the state includes additional content about non-binary gender identity that the Trump administration says is "outside the scope" of the grant's purpose.

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

A multi-institutional team led by Weill Cornell Medicine has received a five-year, $14.9 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes ...

Governor Seyi Makinde of Oyo State has approved a sum of ₦45 million for the Oyo State Agency for the Control of AIDS (OYSACA) ...

Why do people infected with the human immunodeficiency virus (HIV) often suffer from cardiovascular, liver, and other comorbidities? Researchers at the Center for Individualized Infection Medicine ...

The Clark County Health Department says private funds are sustaining some efforts as federal funding and guidance changes.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

This August, First Baptist Church in Austin hosts a memorial that renders that faith tangible. Large quilts, each a tapestry ...

Honesty Bishop was attacked by her cellmate. Prison officials deemed her sexually active and kept her in isolation for more than 2,000 days.

In people with HIV infection, new-onset diabetes is independently predicted by higher leukocyte counts — mostly within the ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...